<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631303</url>
  </required_header>
  <id_info>
    <org_study_id>2018.246</org_study_id>
    <nct_id>NCT03631303</nct_id>
  </id_info>
  <brief_title>Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias</brief_title>
  <acronym>A PRIORY</acronym>
  <official_title>Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patients at increased risk for sudden cardiac death (SCD) may receive an
      implantable cardioverter defibrillator (ICD). The primary criterion for a primary prevention
      ICD implantation is a left ventricular ejection fraction (LVEF) below 35%, but refinement of
      ICD criteria is important since only a small proportion of ICD patients receives appropriate
      device therapy (ATP or a shock) during follow-up. Post-extrasystolic potentiation (PESP) may
      be a new risk marker for SCD. PESP is defined as a temporary increase in contractility that
      follows an extrasystolic beat (ESB) and is associated with myocardial calcium handling. In
      heart failure, changes in calcium homeostasis may lead to afterdepolarisations and thus
      predispose for SCD. PESP can be measured indirectly and non-invasively as post-extrasystolic
      blood pressure potentiation (PESP-BP). Abnormal PESP-BP was previously found to be an
      independent predictor of increased mortality in post-myocardial infarction patients with a
      reduced LVEF. However, it is unknown if this increased mortality in heart failure patients
      with abnormal PESP-BP is caused by an increased risk of SCD.

      Hypothesis: The investigators hypothesize that PESP-BP might be a new predictor of the
      occurrence of SCD, and can be used to enhance patient selection for primary prevention ICD
      therapy.

      Design: During scheduled device replacement ESB with various extrasystolic and
      post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right
      atrial and ventricular device leads of the patient. Throughout the stimulation study blood
      pressure will be measured non-invasively a continuous electrocardiogram will be recorded.
      Either before or after the procedure, patients will undergo a 30-minutes assessment of
      spontaneous ESB, again with blood pressure and ECG recordings.

      Study population: 30 patients who are scheduled for device replacement or reposition, are
      eligible for this study; (1) 10 ICD patients who previously received appropriate device
      therapy (ADT); (2) 10 ICD patients who are free from ADT and (3) 10 dual-chamber pacemaker
      patients (control group).

      Outcomes: (1) Evoked PESP-BP (i.e. blood pressure differences between baseline, ESB and
      post-ESB); (2) Spontaneous PESP-BP (i.e. blood pressure differences between baseline, ESB and
      post-ESB); (3) Timing parameters (in ms): the basic cycle length interval; Extra-systolic
      interval (ESI); Post-extrasystolic interval (PESI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evoked PESP-BP</measure>
    <time_frame>Measured during stimulation protocol</time_frame>
    <description>blood pressure differences between baseline, extrasystolic beat (ESB) and post-ESB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous PESP-BP</measure>
    <time_frame>Measured in rest, without cardiac stimulation with spontaneous ESB</time_frame>
    <description>blood pressure differences between baseline, extrasystolic beat (ESB) and post-ESB</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Post-extrasystolic Potentiation (PESP)</condition>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>ICD patients with ATP/shock</arm_group_label>
    <description>10 primary prevention 2-chamber ICD patients (LVEF &lt;35 percent) who received appropriate ICD therapy during follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICD patients without ATP/Shock</arm_group_label>
    <description>10 primary prevention 2-chamber ICD patients (LVEF &lt;35 percent) who were free from appropriate ICD therapy during follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pacemaker-patients</arm_group_label>
    <description>10 2-chamber pacemaker-patients (LVEF &gt;50%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac stimulation through the device leads</intervention_name>
    <description>During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.</description>
    <arm_group_label>ICD patients with ATP/shock</arm_group_label>
    <arm_group_label>ICD patients without ATP/Shock</arm_group_label>
    <arm_group_label>Pacemaker-patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 patients who are scheduled for device replacement or reposition, are eligible for this
        study; (1) 10 ICD patients who previously received appropriate device therapy (ATP/shock);
        (2) 10 ICD patients who are free from ADT and (3) 10 dual-chamber pacemaker patients
        (control group)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Implanted with a dual-chamber device

          -  For ICD patients: a LVEF ≤35%, measured recently

          -  For Pacemaker patients: a LVEF &gt; 50% measured both recently

          -  A device follow-up of at least one year must be available

          -  Optimal (stable) medical therapy

          -  Sinus rhythm

        Exclusion Criteria:

          -  Age &lt;18 or incapacitated adult

          -  Unknown left ventricular function prior to device implantation

          -  Patients unwilling to participate

          -  Documented atrial fibrillation

          -  Second or third degree atrioventricular (AV) conduction disorders;

          -  Patients with a cardiac resynchronization therapy (CRT-D) or one-chamber device

          -  Hypertrophic cardiomyopathy

          -  Conditions with insufficient blood flow to the fingers, e.g. M. Raynaud or conditions
             with extreme vasoconstriction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelis P. Allaart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cornelis P Allaart, MD, PhD</last_name>
    <phone>+31 (0)20 4445043</phone>
    <email>cp.allaart@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Lotte CJ van der Lingen, MD</last_name>
    <phone>+31 (0)20-4443272</phone>
    <email>a.vanderlingen@vumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU university medical center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Lotte van der Lingen, MD</last_name>
      <phone>+31204443272</phone>
      <email>a.vanderlingen@vumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Steger A, Sinnecker D, Barthel P, Müller A, Gebhardt J, Schmidt G. Post-extrasystolic Blood Pressure Potentiation as a Risk Predictor in Cardiac Patients. Arrhythm Electrophysiol Rev. 2016 May;5(1):27-30. doi: 10.15420/aer.2016.14.2.</citation>
    <PMID>27403290</PMID>
  </reference>
  <reference>
    <citation>Sinnecker D, Dirschinger RJ, Barthel P, Müller A, Morley-Davies A, Hapfelmeier A, Dommasch M, Huster KM, Hasenfuss G, Laugwitz KL, Malik M, Schmidt G. Postextrasystolic blood pressure potentiation predicts poor outcome of cardiac patients. J Am Heart Assoc. 2014 Jun 3;3(3):e000857. doi: 10.1161/JAHA.114.000857.</citation>
    <PMID>24895163</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Cornelis P. Allaart</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <keyword>Post-extrasystolic Potentiation</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

